Different guidelines for the management of hidradenitis suppurativa have emerged in recent years. As they are all based on the same data of evidence, a joint venture for consolidation would be desirable, argued Prof. Gregor Jemec (Zealand University Hospital, Denmark).
Hidradenitis suppurativa (HS) is a chronic, systemic condition with recurrent painful deep-seated nodules, sinus tracts, and abscesses that gravely impacts quality of life . Appropriate treatment is often delayed due to under-recognition. “Many different organisations have created guidelines for the treatment of hidradenitis suppurativa independently of each other, and my conclusion is that we should really work together on these guidelines,” said Prof. Jemec . The European guidelines were published in 2015. They were followed by the British guidelines in 2018 and North American in 2019 [3,4,5]. These guidelines are based on the same body of evidence that lead them to similar recommend...
Please login to read the full text of the article.
If you have no account yet, please register now.
« Management strategies for drug-induced mucositis Next Article
Biologics: biosimilars and lifestyle »